Ambartsumian N, Klingelhfer J, Grigorian M. The multifaceted S100A4 protein in cancer and inflammation[J]. Methods Mol Biol,2019,1929(1):339-365.
[2]
Li Z, Li Y, Liu S, et al. Extracellular S100A4 as a key player in fibrotic diseases[J]. J Cell Mol Med, 2020, 24(11):5973-5983.
[3]
Athanasiou A T, Nussbaumer T, Kummer S, et al. S100A4 mRNA-protein relationship uncovered by measurement noise reduction[J]. J Mol Med (Berl), 2020, 98(5):735-749.
[4]
Kim B, Jung S, Kim H, et al. The role of S100A4 for bone metastasis in prostate cancer cells[J]. BMC Cancer,2021, 21(1):137.
[5]
Sakic A, Chaabane C, Ambartsumian N, et al. Neutralization of S100A4 induces stabilization of atherosclerotic plaques: role of smooth muscle cells[J]. Cardiovasc Res,2022, 118(1):141-155.
[6]
Yao C Y, Lin C C, Wang Y H, et al. The clinical and biological characterization of acute myeloid leukemia patients with S100A4 overexpression[J]. J Formos Med Assoc, 2022, 6646(22):422-423.
[7]
Zou S, Huang Z, Wu J. Predictive value of S100A4 in eosinophilic chronic rhinosinusitis with nasal polyps[J]. Front Surg, 2022,1(9):989489.
[8]
Fissolo N, MatuteB C, Osman M, et al. CSF SERPINA3 levels are elevated in patients with progressive MS[J]. Neurol Neuroimmunol Neuroinflamm,2021, 8(2):941.
[9]
Neidhart M, Pajak A, Laskari K, et al. Oligomeric S100A4 is associated with monocyte innate immune memory and bypass of tolerance to subsequent stimulation with lipopolysaccharides[J]. Front Immunol,2019, 15(10):791.
[10]
Yang L, Song L, Ma D, et al. Plasma S100A4 level and cardiovascular risk in patients with unstable angina pectoris[J]. Biomark Med, 2019, 13(17):1459-1467.
[11]
Cai X, Zhang L, Wang X. S100A4 is expressed in human odontoblasts and odontoblast-like cells[J]. Tissue Cell,2022, 79:101959.
[12]
Li Z, Li Y, Liu S, et al. Extracellular S100A4 as a key player in fibrotic diseases[J]. J Cell Mol Med, 2020, 24(11):5973-5983.
[13]
Gangadaran P, Oh E J, Rajendran R L, et al. Identification of angiogenic cargoes in human fibroblasts-derived extracellular vesicles and induction of wound healing[J]. Pharmaceuticals (Basel), 2022, 15(6):702.
[14]
Sen Chaudhuri A, Yeh Y W, Zewdie O, et al. S100A4 exerts robust mucosal adjuvant activity for co-administered antigens in mice[J]. Mucosal Immunol, 2022, 15(5):1028-1039.
[15]
Hsieh Y Y, Cheng Y W, Wei P L, et al. Repurposing of ingenolmebutate for treating human colorectal cancer by targeting S100 calcium-binding protein A4 (S100A4)[J]. Toxicol Appl Pharmacol, 2022, 15(449):116-134.
[16]
Wen J, Jiao B, Tran M, et al. Pharmacological inhibition of s100a4 attenuates fibroblast activation and renal fibrosis[J]. Cells, 2022, 11(17):2762.
[17]
Stark J M, Tibbitt C A, Coquet J M. The metabolic requirements of Th2 cell differentiation[J]. Front Immunol,2019, 27(10):2318.
[18]
Huang X, Qu D, Liang Y, et al. Elevated S100A4 in asthmatics and an allergen-induced mouse asthma model[J]. J Cell Biochem,2019, 120(6):9667-9676.
[19]
Wu T, Ma L, Jin X, et al. S100A4 is critical for a mouse model of allergic asthma by impacting mast cell activation[J]. Front Immunol, 2021, 22(12):692-733.
[20]
Dukhanina E A, Portseva T N, Dukhanin A S, et al. Triple-negative and triple-positive breast cancer cells reciprocally control their growth and migration via the S100A4 pathway[J]. Cell Adh Migr, 2022, 16(1):65-71.
[21]
Qi Y, Zhao T, Li R, et al. Macrophage-secreted S100a4 supports breast cancer metastasis by remodeling the extracellular matrix in the premetastatic niche[J]. Biomed Res Int,2022, 20(2022):9895504.
[22]
Wu Y, Zhang W, Gunst S J. S100A4 is secreted by airway smooth muscle tissues and activates inflammatory signaling pathways via receptors for advanced glycation end products[J]. Am J Physiol Lung Cell Mol Physiol,2020, 319(1):185-195.
[23]
Zhang H, Liu S, Li Y, et al. Dysfunction of S100A4+ effector memory CD8+ T cells aggravates asthma[J]. Eur J Immunol,2022, 52(6):978-993.
[24]
Maurer M, Zuberbier T, Metz M. The classification, pathogenesis, diagnostic workup, and management of urticaria: an update[J]. Handb Exp Pharmacol, 2022, 268(3):117-133.
[25]
Inukai M, Yokoi A, Ishizuka Y, et al. A functional role of S100A4/non-muscle myosin IIA axis for pro-tumorigenic vascular functions in glioblastoma[J]. Cell Commun Signal, 2022, 20(1):46.
[26]
He L, Yi W, Huang X, et al. Chronic urticaria: advances in understanding of the disease and clinical management[J]. Clin Rev Allergy Immunol, 2021, 61(3):424-448.
[27]
Mitrovic Ajtic O, Suboticki T, Diklic M, et al. Regulation of S100 as expression by inflammatory cytokines in chronic lymphocytic leukemia[J]. Int J Mol Sci, 2022, 23(13):6952.
[28]
Tabaa M M E, Fattah A M K, Shaalan M, et al. Dapagliflozin mitigates ovalbumin-prompted airway inflammatory-oxidative successions and associated bronchospasm in a rat model of allergic asthma[J]. Expert Opin Ther Targets,2022, 26(5):487-506.
[29]
Jiang J X, Shen H J, Guan Y, et al. ZDHXB-101 (3′,5-Diallyl-2, 4′-dihydroxy-[1,1′-biphen-yl]-3, 5′-dicarbaldehyde) protects against airway remodeling and hyperresponsiveness via inhibiting both the activation of the mitogen-activated protein kinase and the signal transducer and activator of transcription-3 signaling pathways[J]. Respir Res, 2020, 21(1):22.
[30]
Jiang J X, Guan Y, Shen H J, et al. Inhibition of soluble epoxide hydrolase attenuates airway remodeling in a chronic asthma model[J]. Eur J Pharmacol,2020, 5(868):172874.
[31]
Sundberg J P, Pratt C H, Goodwin L P, et al. Keratinocyte-specific deletion of SHARPIN induces atopic dermatitis-like inflammation in mice[J]. PLoS One, 2020, 15(7):0235295.
[32]
Treese C, Hartl K, Ptzsch M, et al. S100A4 is a strong negative prognostic marker and potential therapeutic target in adenocarcinoma of the stomach and esophagus[J]. Cells, 2022, 11(6):1056.
[33]
Wu L D, Li F, Chen J Y, et al. Analysis of potential genetic biomarkers using machine learning methods and immune infiltration regulatory mechanisms underlying atrial fibrillation[J]. BMC Med Genomics, 2022, 15(1):64.
[34]
Qin H Y, Li M D, Xie G F, et al. Associations among S100A4, sphingosine-1-phosphate, and pulmonary function in patients with chronic obstructive pulmonary disease[J]. Oxid Med Cell Longev, 2022, 2022:6041471.
[35]
Laggner M, Hacker P, Oberndorfer F, et al. The roles of S100A4 and the EGF/EGFR signaling axis in pulmonary hypertension with right ventricular hypertrophy[J]. Biology (Basel),2022, 11(1):118.
[36]
Dahlmann M, Monks A, Harris E D, et al. Combination of Wnt/β-catenin targets S100A4 and DKK1 improves prognosis of human colorectal cancer[J]. Cancers (Basel), 2021, 14(1):37.
[37]
Rodrigues M A, Gomes D A, Cosme A L, et al. Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4)[J]. Biomed Pharmacother,2022, 145:112403.
[38]
Qian L, Gong J, Ma W, et al. Circulating S100A4 as a prognostic biomarker for patients with nonparoxysmal atrial fibrillation after catheter ablation[J]. Ann Transl Med, 2021, 9(18):1400.
[39]
Yildirim A, Tekpinar M, Wassenaar T A. Competing roles of Ca2+ and nonmuscle myosin iia on the dynamics of the metastasis-associated protein S100A4[J]. J Phys Chem B. 2021, 125(36):10059-10071.
[40]
Davis J L, Thaler R, Cox L, et al. Constitutive activation of NF-κB inducing kinase (NIK) in the mesenchymal lineage using Osterix (Sp7)- or Fibroblast-specific protein 1 (S100A4)-Cre drives spontaneous soft tissue sarcoma[J]. PLoS One, 2021,16(7):e0254426.
[41]
Tamura T, Miyata T, Hatori K, et al. Role of S100A4 in the pathogenesis of human periapical granulomas[J]. In Vivo, 2021, 35(4):2099-2106.
[42]
Liu S, Zhang H, Li Y, et al. S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation[J]. J Immunother Cancer, 2021, 9(6):e002548.
[43]
Milani M, Mammarella E, Rossi S, et al. Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis[J]. J Neuroinflammation, 2021, 18(1):132.
[44]
Maddala R, Gao J, Mathias R T, et al. Absence of S100A4 in the mouse lens induces an aberrant retina-specific differentiation program and cataract[J]. Sci Rep, 2021, 11(1):2203.
2023, Vol. 34 
